ClinicalTrials.Veeva

Menu

First Optical Coherence Microscopy in Dermato-oncology (GALAXY)

C

Centre Hospitalier Universitaire de Saint Etienne

Status

Completed

Conditions

Skin Cancer

Treatments

Device: OCTAV Patient
Device: OCTAV Control group

Study type

Interventional

Funder types

Other

Identifiers

NCT03079232
1608015
2016-A00319-42 (Other Identifier)

Details and patient eligibility

About

OCTAV is a medical device class I, not CE marked, based on a new technique for high-resolution imager (cell) internal microstructures of all types of biological tissues in vivo or ex vivo, to a depth of penetration 800 .mu.m. It allows to explore the epidermis, the dermo-epidermal junction and middle dermis in a totally non-invasive (direct contact with the tissue without sampling).

Full description

At the coming of the patient in Dermatology for resection / biopsy of the tumor (usual practice), for the study, an image of the tumor will be performed with the OCTAV device (about 5 minutes) for the study. Then, according to usual practice, resection / biopsy will be performed.

This study aims to validate the clinical relevance of this device to characterize the 3 main skin cancers and to obtain the necessary data for the implementation of future clinical trials.

Enrollment

122 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

FOR PATIENT

Inclusion Criteria:

  • Patient with a cutaneous lesion suspicious for melanoma, basal cell carcinoma, squamous cell carcinoma, requiring a surgical excision
  • Consent form signed
  • Major patient

Exclusion Criteria:

  • Allergy or intolerance to immersion oil (used for microscopy)
  • If female, pregnant or breast-feeding
  • Patient unable to stand still for 60 seconds
  • Skin lesions located near patient eyes (<3 cm)

FOR CONTROL GROUP

Inclusion Criteria:

  • Aged between 18 to 40 years
  • Consent form signed
  • Patient of the dermatology department with non-pathological forearm skin

Exclusion Criteria:

  • Allergy or intolerance to immersion oil (used for microscopy)
  • If female, pregnant or breast-feeding
  • Patient unable to stand still for 60 seconds

Trial design

Primary purpose

Diagnostic

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

122 participants in 2 patient groups

OCTAV Patient
Experimental group
Description:
The patients who will have a biopsy of skin suspected to be a melanoma, basal cell carcinoma or squamous cell carcinoma will have a skin imaging with a new Microscopy Optical Coherence (OCTAV)
Treatment:
Device: OCTAV Patient
OCTAV Control group
Experimental group
Description:
Control group (patients without skin cancer) will have a skin imaging with a new Microscopy Optical Coherence (OCTAV)
Treatment:
Device: OCTAV Control group

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems